Blood pressure and chronic kidney disease progression in a multi-racial cohort: The Multi-Ethnic study of atherosclerosis

Journal of Human Hypertension

Volumn 27, Issue 7, 2013, Pages 421-426

  Bloomfield, G S ^a,b   Yi, S S ^c   Astor, B C ^c,d,e   Kramer, H ^f   Shea, S ^g,h   Shlipak, M G ^i,j   Post, W S ^c,e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g Department of Medicine   (United States)

^h New York Presbyterian Columbia University Medical Center   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYSTATIN C;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; RISK FACTOR;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CREATININE; CYSTATIN C; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HISPANIC AMERICANS; HUMANS; HYPERTENSION; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84879419922     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.1     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention (CDC). Hypertension-related mortality among hispanic subpopulations-United States, 1995-2002. MMWR 2006; 55(7): 177-180.
2. Kramer H, Han C, Post W, Goff D, Diez-Roux A, Cooper R et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 2004; 17(10): 963-970. (Pubitemid 39361670)
3. Kurth T, Jong PED, Cook NR, Buring JE, Ridker PM. Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study. BMJ 2009; 338(1): b2392.
4. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008; 51(4 Suppl 2): S30-S37. (Pubitemid 351444715)
5. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288(19): 2421-2431. (Pubitemid 35340538)
6. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis 2010; 55(4): 671-681.
7. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244-252.
8. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142(5): 342-351. (Pubitemid 40293407)
9. Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M et al. Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension 2011; 57(6): 1061-1068.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105-1187. (Pubitemid 46924065)
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572. (Pubitemid 37430158)
12. Djamali A, Kendziorski C, Brazy PC, Becker BN. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 2003; 64(5): 1800-1807. (Pubitemid 37323710)
13. National Institutes of Health, National Institute of Diabetes and Kidney Disease. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Kidney Disease: Bethesda, MD, 2009.
14. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22(1): 147-155.
15. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002; 156(9): 871-881. (Pubitemid 35215769)
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J of Kidney Dis 2002; 39(2 Suppl 1): S1-S246.
17. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51(3): 395-406. (Pubitemid 351273480)
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 461-470. (Pubitemid 29135798)
19. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367(1): 20-29.
20. Kramer H, Palmas W, Kestenbaum B, Cushman M, Allison M, Astor B et al. Chronic kidney disease prevalence estimates among racial/ethnic groups: the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol 2008; 3(5): 1391-1397.
21. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009; 204(1): 298-303.
22. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168(20): 2212-2218.
23. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363(10): 918-929.
24. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330(13): 877-884. (Pubitemid 24094966)
25. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365(9463): 939-946. (Pubitemid 41071427)
26. Groesbeck D, Kö ttgen A, Parekh R, Selvin E, Schwartz GJ, Coresh J et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol 2008; 3(6): 1777-1785.
27. Peralta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Lin F et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005; 45(6): 1119-1124. (Pubitemid 40770315)
28. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75(6): 652-660.
29. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36(1): 29-34. (Pubitemid 30432560)
30. Roos JF, Doust J, Tett SE, Kirkpatrick CMJ. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis. Clin Biochem 2007; 40(5-6): 383-391.
31. Bloch MJ, Basile J. African American patients with hypertensive chronic kidney disease receive no benefit on kidney disease progression from the currently recommended blood pressure goal of o130/80mmHg unless there is significant proteinuria at baseline: long-term follow-up of the AASK study. J Clin Hypertens 2011; 13(3): 214-216.